Page 43 - Solid Tumors News Today

01.08.2022 - ~ Under the Terms of the Investment Agreement, $5 Million to be Funded on initial closing and $20 Million to be Funded Upon Potential FDA Approval of PEDMARKTM ~ ~ Fennec Has the Potential to Access an Additional $20 Million Prior to December 31, ... Seite 1

Seven NCI sponsored trials will evaluate safety and efficacy of its BET inhibitor (BETi) ZEN-3694 in combination with several targeted agents and/or...

JERSEY CITY, N.J., July 6, 2022 /PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Vascular Disrupting Agents Market By Indications

/PRNewswire/ -- InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the " "Global Vascular Disrupting Agents Market By...

–Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses––Results presented in late-breaking oral session at the ESMO World Congress on Gastrointestinal Cancer–BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced full results from...

-Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses- -Results presented in late-breaking oral session at the ESMO World Congress

–Phase 2 trial showed chemotherapy-free TUKYSA combination resulted in clinically meaningful and durable tumor responses– –Results presented in late-b

/PRNewswire/ -- The Mark Foundation for Cancer Research today announces a new ~$12 million grant to support a global team developing novel immunotherapies for...

06/15/22 Clinical Leader Newsletter


/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the...